MAIA Biotechnology to Present at Biotech Showcase 2025

Rhea-AI Summary

MAIA Biotechnology (NYSE: MAIA) has announced its participation in the Biotech Showcase™ 2025 investor conference, scheduled for January 13-15, 2025, in San Francisco, with a follow-up virtual event on January 21-22, 2025.

CEO Vlad Vitoc, M.D. will present on January 13, 2025, at 3:00 PM PST, discussing key developments including:

• Expansion of the THIO-101 pivotal Phase 2 clinical trial for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy
• Plans for multiple THIO trials across additional cancer indications
• Market potential for THIO in major tumor types globally

The presentation will be available via webcast with on-demand playback accessible for 6 months following the event. Dr. Vitoc will also conduct one-on-one meetings with investors throughout the conference.

• CEO to detail THIO-101 expansion trial and upcoming trials in multiple indications

CHICAGO--(BUSINESS WIRE)-- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that Chief Executive Officer Vlad Vitoc, M.D. will present at the Biotech Showcase™ 2025 investor conference taking place in San Francisco, California January 13-15, 2025. Dr. Vitoc will also host one-on-one meetings with investors throughout the 3-day event. The live event will be followed by a virtual 2-day event on January 21-22, 2025.

At the conference, Dr. Vitoc will discuss MAIA’s recent clinical developments and targeted value-driving milestones for 2025 and beyond, including:

• Expansion of MAIA’s THIO-101 pivotal Phase 2 clinical trial to further assess the efficacy of telomere-targeting agent THIO in advanced non-small cell lung cancer (NSCLC) patients receiving third line (3L) therapy.
• Multiple THIO trials planned for additional cancer indications.
• Significant market opportunity for THIO in the top tumor types globally.

Biotech Showcase conference details:
Dates:	Live event January 13-15, 2025; Digital event January 21-22, 2025
MAIA presentation:	03:00PM PST on Monday, January 13, 2025*
Conference registration:	All-access and Digital passes available on the conference website
One-on-One Meetings:	Bookings available on the conference website
Webcast:	Join here for live presentation and virtual event streaming
On-demand playback:	Available here 2 hours after the presentation, accessible for 6 months

*Please note that the presentation date and time are subject to change. Attendees can refer to the program agenda for conference updates.

About THIO

THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. THIO is presently developed as a third line of treatment for NSCLC for patients that are resistant to checkpoint inhibitors and chemotherapy.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250110421381/en/

Investor Relations Contact

+1 (872) 270-3518

ir@maiabiotech.com

Source: MAIA Biotechnology, Inc.

FAQ

What are the key developments MAIA Biotechnology will present at Biotech Showcase 2025?

MAIA will present the expansion of THIO-101 Phase 2 trial for NSCLC, plans for additional THIO trials in various cancer indications, and discuss the market opportunity for THIO in major tumor types globally.

When and where will MAIA Biotechnology present at Biotech Showcase 2025?

MAIA will present on January 13, 2025, at 3:00 PM PST during the live event in San Francisco, California, with a virtual event following on January 21-22, 2025.

What is the focus of MAIA's THIO-101 Phase 2 clinical trial?

The THIO-101 Phase 2 clinical trial focuses on evaluating the efficacy of telomere-targeting agent THIO in advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy.

How long will the Biotech Showcase 2025 presentation be available for viewing?

The presentation will be available for on-demand playback for 6 months following the event through the conference website.

What opportunities will be available for investors at the Biotech Showcase 2025?

Investors can attend the live presentation, access the digital event, and book one-on-one meetings with CEO Dr. Vlad Vitoc throughout the 3-day conference.